Table 2.

Univariate analysis and multivariate logistic regression assessing risk factors for transient bradycardia and for mortality.

Transient Bradycardia	Univariate analysis		Multivariate analysis
	OR (95% CI)	p	OR (95% CI)	p
Female sex	1.62 (0.807–3.256)	0.175
Age	1.025 (1.000–1.051)	0.048	1.016 (0.986–1.047)	0.291
CVD	2.1 (1.011–4.362)	0.047	1.628 (0.643–4.125)	0.304
Beta-blockers	1.385 (0.671–2.86)	0.378	0.935 (0.389–2.244)	0.88
T ≥38°C	1.075 (0.421–2.742)	0.88
Lymphocytes	1 (0.999–1)	0.402
C-RP	1.027 (0.982–1.074)	0.246
d-dimer	1 (1-1)	0.934
RDV therapy	2.277 (1.13–4.588)	0.021	2.153 (1.052–4.405)	0.036
PaO2/FiO2 <300	1.161 (0.577–2.337)	0.676
Mortality
Female sex	0.405 (0.156–1.049)	0.063	0.267 (0.072–0.997)	0.049
Age	1.138 (1.072–1.208)	<0.001	1.138 (1.046–1.238)	0.003
CCI	1.63 (1.281–2.074)	<0.001	0.977 (0.636–1.499)	0.914
Days onset-admission	0.799 (0.679–0.94)	0.007	0.759 (0.603–0.956)	0.019
PaO2/FiO2 <300	1.523 (0.62–3.738)	0.359
Pneumonia	1.029 (0.273–3.875)	0.966
T ≥38°C	1.447 (0.479–4.373)	0.655
Lymphocytes	0.999 (0.998–1)	0.256
C-RP	1.082 (1.024–1.143)	0.005	1.11 (1.022–1.206)	0.013
IL-6a	1 (0.999–1.002)	0.58
d-dimer	1.0001 (1–1.0003)	0.055	1 (1-1)	0.78
CD4/CD8	0.62 (0.326–1.179)	0.145
LMWH administration	0.198 (0.012–3.286)	0.259
Steroids administration	5.806 (0.332–101.45)	0.228

Abbreviations: OR, odds ratio; CI, confidential interval; CVD, cardiovascular diseases, T, body temperature; C-RP, C-reactive protein; RDV, remdesivir; CCI, Charlson comorbidity index; IL-6, interleukin 6; LMWH, low molecular weight heparin.